Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6347549 | 0.89 | HSD11B1 (0.48) | HSD11B1CES2CES1HTR1AADRA2A | |
| SCHEMBL6352526 | 0.89 | PARP1 (0.49) | HSD11B1CES2CES1HTR1AADRA2A | |
| SCHEMBL6356051 | 0.83 | ALDH1A1 (0.45) | CES1ADRA2AKCNH2NPC1RAB9A | |
| SCHEMBL6349361 | 0.83 | ALDH1A1 (0.45) | CES1ADRA2AKCNH2NPC1RAB9A | |
| SCHEMBL6350978 | 0.83 | ALDH1A1 (0.45) | CES1ADRA2AKCNH2NPC1RAB9A | |
| SCHEMBL6347116 | 0.81 | CA12 (0.47) | LMNASMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL6349745 | 0.80 | TRPM8 (0.54) | HSD11B1CES2CES1HTR1AADRA2A | |
| SCHEMBL664955 | 0.77 | CES2 (0.61) | HSD11B1CES2CES1PARP1CHRM2 | |
| SCHEMBL6350477 | 0.77 | L3MBTL1 (0.51) | HSD11B1CES2CES1OPRM1NPC1 | |
| SCHEMBL6350485 | 0.74 | KMT2A (0.44) | CES1NPC1RAB9ALMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960575-B2 | For use as inhibitors of chymase | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20040097496-A1 | Novel thiazine derivatives | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1211249-A1 | NOVEL THIAZINE OR PYRAZINE DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097496-A1 | Novel thiazine derivatives | CMA1, TPSD1, HRH4 | HSD11B1 604/4885CES2 866/4885CES1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.